Core Viewpoints - The report indicates that the retail financial business of the company maintains resilience, with retail loan growth aligning with overall loan growth, and the proportion remaining stable. Small and micro loans have seen rapid growth, increasing their share of retail loans, while the overall pricing of retail loans is lower than the average of joint-stock banks, leading to a continuous narrowing of the pricing gap [6][9] - Retail deposits have surpassed retail loans, resulting in a positive internal interest net income, which supports the net interest income of retail financial business. Although there is a negative growth in net fee income, the continuous growth in retail customer AUM and the recovery trend in wealth management-related business sales may help stabilize net fee income in the retail sector [6][9] - The report highlights that the attention and overdue rates of some retail loans are still rising, while the overall loan provision remains high. The non-performing loan ratio for corporate loans continues to decline, and the overall non-performing loan ratio remains stable. The bank's provision coverage and loan provision ratios are both maintained at high levels, indicating potential for release [6][9] - The report notes that the current account ratio of deposits is at a relatively high level among listed banks, with a significant cost advantage in deposits. Although the trend of increasing fixed-term deposits continues, the bank's management of retail and corporate deposit costs remains effective [6][9] - The earnings forecast suggests that the company is expected to achieve revenue growth rates of -3.33%, 5.2%, and 4.67% for 2024 to 2026, with net profit growth rates of 1.35%, 5.85%, and 5.54% respectively. The estimated EPS for these years are 5.89, 6.24, and 6.58 yuan [6][9]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 15% in the next six months [2][94]. Core Insights - The retail financial business shows resilience, with retail loans growing at a rate comparable to total loan growth, and the proportion of retail loans remaining stable. Small and micro loans have seen rapid growth, increasing their share of retail loans [1][19]. - Retail deposits have surpassed retail loans, leading to a positive internal net interest income, which supports the interest income from retail financial services. However, net fee income has experienced negative growth [1][27]. - The asset quality of retail loans has shown some volatility, with rising attention and overdue rates, while corporate loan non-performing rates continue to decline [1][54]. - The bank's deposit liquidity ratio remains high compared to listed banks, and it maintains a significant cost advantage in deposits [1][73]. - The bank's strong capital position supports stable future asset expansion, and the resilience of its retail financial business is expected to stabilize fee income as wealth management sales recover [1][79]. Summary by Sections Retail Financial Business Resilience - Retail loan growth is stable, with retail loans accounting for 52.5% of total loans as of June 2024, while corporate loans account for 41.1% [19][20]. - The proportion of small and micro loans has increased by 5.1 percentage points since 2020, while the overall pricing of retail loans is below the average of listed banks, with a narrowing gap of 50 basis points [21][23]. - Retail financial business revenue contribution remains high, with revenues of 194.3 billion yuan in 2023 and 95.9 billion yuan in the first half of 2024, showing a year-on-year growth of 1.5% and a decline of 3% respectively [27][45]. Asset Quality and Provisions - Retail loan non-performing rates have fluctuated, but corporate loan non-performing rates have shown a steady decline. The overall non-performing rate remains stable [54][63]. - The bank's provision coverage ratio is at 432.15%, indicating a strong buffer against potential loan losses [70][72]. Deposit Liquidity and Cost Advantage - The bank's deposit liquidity ratio exceeds 50%, with retail deposits growing at a rate of 8.9% in the first half of 2024, outpacing total deposit growth [73][74]. - The average cost of retail deposits is 1.51%, while corporate deposits are at 1.68%, reflecting effective cost management [74][75]. Capital Strength and Future Outlook - As of June 2024, the bank's core tier one capital adequacy ratio stands at 13.86%, providing a solid foundation for future asset expansion [79][80]. - The bank's earnings forecast for 2024-2026 indicates a revenue growth rate of -3.33%, 5.2%, and 4.67%, with net profit growth rates of 1.35%, 5.85%, and 5.54% respectively [88][89].

[Table_Title] 万联晨会 [Table_MeetReportDate] 2024 年 12 月 09 日 星期一 [Table_Summary] 概览 核心观点 【市场回顾】 上周五，A 股震荡攀升，上证综指涨 1.05%，报 3404.08 点，深证成 指涨 1.47%，创业板指涨 2.05%。A 股两市全天成交额约 17,885.97 亿 元人民币，全天超 3500 股上涨。南向资金净买入 49.78 亿港元。申 万行业方面，传媒、钢铁行业领涨，综合、通信涨幅靠后；概念板块 方面，Sora 概念（文生视频）、互联网保险涨幅居前，PEEK 材料、海 南自贸区涨幅靠后。港股方面，香港恒生指数涨 1.56%，恒生科技指 数涨 2.16%。海外方面，美国三大股指涨跌不一，道指跌 0.28%，标 | --- | --- | --- | |---------------------------------------------------|-----------|----------| | [Table_InnerMarketIndex] 国内市场表现 \n指数名称 | \n 收盘 | 涨跌幅 % | ...

Fiscal Policy - The fiscal policy for 2025 is expected to remain loose, with a deficit rate potentially exceeding 3%, rising to 3.5% or higher[4] - The anticipated broad fiscal gap is expected to exceed CNY 10 trillion[4] - Special government bonds issuance is projected to increase, with an expected issuance of CNY 1 trillion in 2025 to support key areas[4] Monetary Policy - Monetary policy will continue to be proactive, with room for interest rate cuts and reserve requirement ratio reductions[4] - The central bank's tools will remain innovative, focusing on maintaining reasonable liquidity levels[4] - Credit supply is expected to remain ample, with a gradual recovery in credit demand anticipated[4] Economic Growth - The economic growth target for 2025 is set around 5%[3] - Structural adjustments in the economy are ongoing, with a focus on transitioning to domestic demand-driven growth[4] - Industrial production is expected to remain robust, with high-tech sectors continuing to show growth advantages[4] Real Estate Market - The real estate market is expected to stabilize, with policies aimed at mitigating risks and supporting demand[4] - The decline in real estate sales is expected to narrow, with a focus on improving cash flow for property companies[4] Investment Trends - Infrastructure and manufacturing sectors are expected to continue driving investment, supported by fiscal spending[4] - The anticipated issuance of special bonds will extend to new infrastructure and urban renewal projects[4] Consumer Behavior - Consumer spending is gradually recovering, with policies aimed at boosting consumption expected to expand[4] - High savings rates among residents remain a concern, indicating cautious consumer sentiment[4] Export Challenges - Exports face increasing uncertainties, particularly regarding trade relations with the U.S.[4] - The pressure on export prices is expected to persist, impacting profit margins for processing enterprises[4] Capital Market Outlook - Structural opportunities in the equity market are anticipated, with a focus on mergers and acquisitions[4] - The bond market is expected to experience increased volatility, with a long-term downward trend remaining intact[4] Risk Factors - Potential risks include unexpected changes in overseas policies and geopolitical tensions[4] - The effectiveness of domestic policies in stabilizing the economy remains a critical area of focus[4]

Group 1: Market Indicators - The major A-share indices rose during the week of December 2 to December 6, with the Shanghai Composite Index showing the largest increase of 2.33% [10][12] - The average daily trading volume in the two markets increased by 13.16% compared to the previous week, reaching 17,235.23 billion yuan, with the electronics sector being the most active [12][13] - Among the Shenwan first-level industries, the comprehensive, machinery equipment, and coal sectors had the highest gains, with increases of 4.66%, 4.62%, and 4.15% respectively [10][12] Group 2: Valuation Levels - As of December 6, the dynamic price-to-earnings (PE) ratio of the Sci-Tech Innovation 50 index is at a historical percentile of approximately 90.77%, the highest among major A-share indices since 2010 [28][30] - Twelve industries, including comprehensive, computer, coal, electronics, and defense military, are above the historical 50th percentile based on their current dynamic PE ratios [30][31] - The current price-to-book (PB) ratios for the computer, coal, electronics, and defense military sectors are also above the historical 50th percentile, indicating relatively high valuations compared to historical averages [30][31] Group 3: Investment Recommendations - The report suggests focusing on passive investment strategies, as index components are expected to benefit continuously [38][39] - It highlights growth sectors related to new productivity, particularly in electronics, AI computing power, and low-altitude economy [38][39]

Investment Rating - The industry investment rating is "Outperform the Market" [4] Core Viewpoints - The film industry has a unique and diversified profit model, relying not only on traditional box office revenue but also on copyright sales, derivative product development, advertising sponsorship, international market expansion, and cooperation with streaming platforms [1][19] - The industry is characterized by cluster development and globalization, with countries implementing cluster strategies to occupy core positions in the industry chain and enhance competitive advantages [20] - The film industry is highly sensitive to economic changes and consumer income levels, indicating a high demand income elasticity [21] Summary by Sections Industry Overview - The film industry encompasses film production, distribution, and exhibition, along with related economic activities such as audio-visual products and cinema construction [1] - The industry chain consists of three interrelated segments: production, distribution, and exhibition, which are crucial for the industry's development [2][26] Offline Market - The revenue model for the offline film industry includes both film revenue and cinema revenue [3] - The box office revenue is subject to a revenue-sharing model where 43% goes to production and distribution companies, while 57% is shared between cinemas and theater chains [3][39] - The box office performance is strongly correlated with release schedules, with significant contributions from key holiday periods [3][41] - As of December 3, 2024, the total box office revenue for the year is 404.47 billion yuan, showing a significant drop compared to 2023 [41][50] Online Market - The online film market is maturing, with a complete industry chain that includes IP supply, film production, and streaming platforms [4][64] - The number of online films released in 2023 decreased significantly compared to previous years, indicating a trend towards fewer but higher-quality productions [67] - Major streaming platforms are upgrading their revenue-sharing models to encourage the production of quality content [78][94] Investment Recommendations - The report suggests focusing on high-quality film production companies and leading cinema chains due to the strong recovery in offline film markets and the anticipated release of several quality films in 2025 [10][101] - In the online film market, attention should be given to leading video platforms that are adapting their revenue-sharing models to enhance content quality and market vitality [10][101]

Investment Rating - The industry investment rating is "Outperform the Market" [4] Core Insights - The launch of the Hongmeng Zhixing Zun Jie S800 has received a positive market response, with over 2,000 pre-orders within 48 hours, indicating strong consumer interest in high-end smart electric vehicles [1] - GAC Group and Huawei have signed a deepening cooperation agreement to leverage their strengths in smart connectivity and manufacturing, aiming to create a new high-end smart electric vehicle brand [2] - The Chinese automotive market is expected to benefit from government policies supporting the replacement of old vehicles and increasing subsidies for new energy vehicles, which may lead to a new growth cycle in the industry [3] Summary by Sections Product Launch - The Zun Jie S800 is priced between 1 million to 1.5 million yuan, featuring advanced design and technology, including L3 intelligent driving capabilities and a new platform for smart driving and cockpit integration [1] Strategic Cooperation - GAC Group plans to develop a new high-end smart electric vehicle brand in collaboration with Huawei, focusing on product development, marketing, and ecosystem services [2] Market Outlook - Government initiatives to support vehicle upgrades and the competitive advantage of Chinese automotive exports are expected to drive steady growth in the automotive sector [3]

[Table_RightTitle] 证券研究报告|食品饮料 | --- | --- | --- | --- | --- | |-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Core Insights - The report highlights a significant decline in the A-share market, with the Shanghai Composite Index falling by 0.42% to 3,364.65 points, and the Shenzhen Component Index dropping by 1.02% [5][2] - The report notes that the U.S. stock indices all closed higher, with the Dow Jones increasing by 0.69% to 45,014.04 points, marking a historical closing high [5][1] - The report indicates that the service sector's activity in China is slowing down, as reflected by the Caixin Services PMI dropping to 51.5 in November, a decrease of 0.5 percentage points from October [2][5] Market Review - The A-share market experienced a sell-off towards the end of the trading session, with notable declines in various indices, including the ChiNext Index, which fell by 1.43% [5][2] - In the Hong Kong market, the Hang Seng Index saw a slight decline of 0.02%, closing at 19,742.46 points, while the Hang Seng Technology Index decreased by 0.32% [5][2] - The report mentions that the total trading volume in the Shanghai and Shenzhen markets reached 1.66 trillion yuan [5][2] Important News - The report states that China's service import and export total reached 61,255.8 billion yuan from January to October, reflecting a year-on-year growth of 14.6% [2][5] - The report highlights that 89 out of 117 drugs successfully entered the National Medical Insurance Drug List through negotiation or bidding, with an average price reduction of 63% [6][7] - The new drug list will officially take effect on January 1, 2025, and includes a total of 3,159 drugs, with 1,765 being Western medicines and 1,394 being traditional Chinese medicines [7][11] Industry Insights - The report emphasizes that the 2024 version of the National Medical Insurance Drug List favors innovative drugs, with 90 out of 91 newly added drugs being launched within the last five years [11][6] - It notes that the success rate for innovative drugs during negotiations exceeded 90%, which is 16 percentage points higher than the overall success rate [11][8] - The report suggests that the adjustment of the drug list indicates a clear policy support for innovative drugs, which is expected to continue expanding their market share [11][7]

Investment Rating - The industry investment rating is "Outperform the Market" (maintained) [2][7]. Core Viewpoints - The National Healthcare Security Administration (NHSA) officially released the 2024 National Medical Insurance Drug List, which includes 117 drugs from outside the directory, with 89 successfully negotiated or bid, achieving a success rate of 76% and an average price reduction of 63%, which is generally consistent with 2023 [2][4]. - The new drug list will be implemented nationwide starting January 1, 2025, with 91 new drugs added to the National Medical Insurance Drug List, of which 89 were included through negotiation or bidding [2][4]. - The adjustment this year primarily focuses on new drugs, with 90 out of the 91 new drugs being launched within the last five years, indicating a strong support for innovative drugs [2][4]. Summary by Sections New Drug Situation - The negotiation and bidding process is the main pathway for new drugs to quickly enter the medical insurance system. This year, 89 drugs entered through negotiation or bidding, a decrease from 121 last year [2][4]. - Among the 91 new drugs, 38 are classified as "global new" innovative drugs, marking a historical high in both proportion and absolute numbers [2][4]. Investment Insights - The report suggests that through seven rounds of adjustments, the quality and structure of drugs within the directory have significantly improved, indicating strong policy support for innovative drugs. The market share of innovative drugs within medical insurance is expected to continue expanding [4]. - Attention is drawn to innovative drug companies that possess commercial potential and can benefit from policy support [4]. Policy and Market Dynamics - The dual-channel management and prescription flow are expected to strengthen further, with effective integration of commercial health insurance and basic medical insurance likely to enhance the level of coverage provided by the directory [4].